dazoxiben has been researched along with Diabetic Retinopathy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De La Cruz, JP; García Campos, J; Moreno, A; Ruiz-Ruiz, MI; Sánchez de la Cuesta, F | 1 |
| De La Cruz, JP; Moreno, A; Ruiz-Ruiz, MI; Sánchez De La Cuesta, F | 1 |
2 other study(ies) available for dazoxiben and Diabetic Retinopathy
| Article | Year |
|---|---|
Effect of camonagrel, a selective thromboxane synthase inhibitor, on retinal vascularization in experimental diabetes.
Topics: Animals; Blood Cell Count; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Enzyme Inhibitors; Fibrinolysis; Imidazoles; Indans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Retinal Neovascularization; Streptozocin; Thromboxane B2; Thromboxane-A Synthase | 1998 |
Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Blood Glucose; Chlorobenzenes; Collagen; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Enzyme Inhibitors; Imidazoles; Male; Platelet Aggregation; Pyridines; Rats; Rats, Wistar; Receptors, Thromboxane; Retinal Vessels; Thromboxane B2; Thromboxane-A Synthase | 2000 |